Objective: To investigate whether a moderate increase in dietary sucrose intake induces different serum lipid responses in normolipidemic subjects with the e2 allele compared with subjects without the e2 allele. Design: Controlled, parallel study. Subjects: There were 15 subjects with the apolipoprotein E (APOE)3/2 genotype and 19 subjects with the APOE3/3 or 3/4 genotype, whose mean7s.d. age was 48714 and 35710 years, respectively. All subjects had normal glucose metabolism. Interventions: The subjects were instructed to increase their sucrose intake by 40 g/day for 8 weeks and to decrease the intake of saturated and unsaturated fat to maintain energy balance. Dietary adherence was monitored using food records and the actual increase in sucrose intake was 39.8718.4 g/day. Sixteen subjects (nine with APOE3/2 genotype, seven with APOE3/3 or 3/4 genotypes) participated also in an 8 h oral fat tolerance test at the beginning and at the end of the intervention. Results: Body weight remained stable during the intervention. Sucrose intake did not have a significant effect on fasting concentrations of serum total and lipoprotein lipids, plasma glucose, serum insulin, squalene and non-cholesterol sterols in either genotype group. Neither were there any changes in postprandial lipid or insulin responses. Conclusions: Moderate increase in sucrose intake does not affect fasting or postprandial serum lipid responses in healthy subjects with or without the e2 allele.
Introduction
Moderation in dietary sucrose is recommended as part of general dietary guidelines (Food and Nutrition Board. Agriculture, 2005) . In regard of cardiovascular disease risk, many short-term studies have suggested a dose-dependent hypertriglyceridemic effect for dietary carbohydrates and sucrose (Parks and Hellerstein, 2000) . However, longer observational studies have not provided evidence of increased risk of coronary heart disease (CHD) (Kushi et al., 1985; Liu et al., 2000) . On the other hand, in a recent study weight gain and risk of type II diabetes were related to consumption of sugar-sweetened beverages in women (Schulze et al., 2004) . The serum triacylglycerol response to dietary carbohydrate could be modified by many factors: type of carbohydrate like sucrose, fructose or starch; other dietary components, introduction rate of sucrose to the diet, transient nature of the response and obesity (Parks and Hellerstein, 2000) .
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Variation in the apolipoprotein E (APOE) gene results in the three common alleles: e2, e3 and e4. It is well known that APOE polymorphism is associated with serum cholesterol concentrations, the carriers of the e4 allele having higher and those with the e2 having lower concentrations than those with the e3 (Dallongeville et al., 1992) . In addition, APOE polymorphism is involved in the metabolism of triacylglycerol-rich lipoproteins. The e2 and e4 alleles have been associated with higher serum triacylglycerol concentrations than the e3 allele in populational studies (Dallongeville et al., 1992) . In a study on patients with CHD, the carriers of the e2 allele were suggested to be more prone to the hypertriglyceridemic effect of sucrose (Erkkilä et al., 2001) . Clearance of triacylglycerol-rich particles could be impaired owing to both the presence of the e2 allele (de Beer et al., 2000) and changes in lipoprotein metabolism by dietary sucrose (Xue et al., 2001; Roberts et al., 2002) . Furthermore, earlier studies have suggested that the polymorphism of the APOE gene is involved in the modification of serum lipid responses to changes in dietary fat quality and amount of cholesterol Miettinen et al., 1992; Sarkkinen et al., 1998; Ordovas, 1999) .
Our aim was to study the potential diet-gene interaction, that is, sucrose-APOE polymorphism in modifying serum lipids. Therefore, we identified healthy subjects with or without the e2 allele for an 8-week study and measured the effect of moderate intake of sucrose on serum fasting and postprandial lipid responses.
Methods

Subjects
Altogether, 65 subjects were screened for eligibility for the study (Figure 1 ). The subjects were recruited from previous studies including determination of the APOE genotype, from the personnel of the University of Kuopio and City of Kuopio. The inclusion criteria were as follows: APOE3/2, 3/3 or 3/4 genotype, age 20-65 years, fasting serum triacylglycerol p3.5 mmol/l, fasting serum cholesterol p8 mmol/l, body mass index (BMI) 18.5-33 kg/m 2 , fasting plasma glucose p6.0 mmol/l and blood pressure p140/90 mm Hg. Furthermore, subjects with unstable angina, revascularization procedures, diabetes, abnormal liver, thyroid or kidney function, excessive alcohol use or inflammatory bowel disease were excluded. Use of lipid-lowering medication or fish oil supplements was not allowed. Of the screened subjects, 18 subjects were eligible for the APOE3/2 group and 35 were eligible for the APOE3/3 or 4/3 group. Of the eligible subjects, 16 and 21 in the groups, respectively, started in the study. Three subjects dropped out from the study; two owing to poor compliance and one owing to medical reasons. Nine women used oral contraceptives, two women used postmenopausal hormone replacement therapy, three subjects used renin-angiotensin system affecting medication, one subject b-blocking agent, one subject antihistamine for allergy and one subject medication to prevent urinary infections. The study subjects gave written consent for participation in the study. The study plan was approved by the Research Ethics Committee, Hospital District of Northern Savo.
Diet
The duration of the intervention was 8 weeks with measurements performed at 0, 4 and 8 weeks. Subjects in both genotype groups were advised to add sucrose consumption by 40 g/day in the form of granulated sugar, sugar-sweetened beverage or jam, which were provided to them. To prevent weight gain, the subjects were advised to reduce fat intake equivalent to 160 kcal per day without a change in the fatty acid composition of the diet by decreasing the use of margarine, oil, butter or fat containing milk, meat or bakery products. Subjects could choose their preferred method of increasing sucrose and reducing fat consumption. Otherwise, the subjects were instructed not to make any other changes in their dietary habits. Figure 1 The subject flow.
Dietary compliance was monitored by 4-day food records at study weeks 3 and 7, and the habitual dietary intake was also estimated by 4-day food record. One of the consecutive recording days was a weekend day. The portion sizes were estimated using household measures or weighed, if applicable. Nutrient intake was calculated using the Micro-Nutrica dietary analysis program (version 2.5, Finnish Social Insurance Institute, Turku, Finland).
Oral fat tolerance test
Qwing to laborious test procedure, 10 subjects with the APOE3/2 and nine subjects with the APOE3/3 or 4/3 from the original sample were recruited for the oral fat tolerance test performed at the beginning and the end of the study. Results from two subjects were rejected because of high fasting serum triacylglycerol concentrations (42 mmol/l) on the morning of the tolerance test and one subject refused to participate in the second test leaving results available in nine and seven subjects from the groups, respectively. Oral fat tolerance test was performed after a 12 h overnight fast. Subjects were advised to avoid strenuous exercise for 1 day and not to drink alcohol for 2 days before the test. After fasting, blood samples were drawn, subjects ate a small rice cake with a piece of cheese (10 g ). Blood samples were drawn after a 12 h overnight fast from an antecubital vein at screening, 0, 4 and 8 weeks. At screening, the APOE genotype was analyzed with the polymerase chain reaction (PCR)-restriction fragment length polymorphism method described by Tsukamoto et al. (1993) with a slight modification. The specific DNA fragment was amplified with PCR with the Primer 1, 5 0 -GCACGGCTGTCCAAGGAGCTGCAGGC-3 0 ; and the Primer 2, 5 0 -GGCGCTCGCGGATGGCGCTGAG-3 0 . PCR amplification was conducted in a 16 ml volume containing 50 ng of genomic DNA, 6.4 pmol of each primer, 10 mmol/l Tris-HCl (pH 8.8), 50 mmol/l KCl, 1.5 mmol/l MgCl 2 , 0.1% Triton X-100, 0.68 U of DNA polymerase (DynaZyme DNA polymerase, Finnzymes, Espoo, Finland), 112.5 mmol/l deoxyribonucleoside triphosphates, and 8.5% glycerol. PCR conditions were denaturation at 961C for 4 min, followed by 35 cycles of denaturation at 961C for 45 s, annealing at 641C for 45 s and extension at 721C for 1 min with final extension at 721C for 4 min. The PCR product was digested with restriction enzyme HhaI (New England Biolabs, Beverly, MA, USA). The digested DNA fragments were separated on 12% polyacrylamide gel. Finally, separated DNA fragments were visualized by ethidium bromide staining. The different genotypes could be distinguished on the basis of the digestion pattern observed under ultraviolet illumination.
Lipoproteins were separated by ultracentrifugation for 18 h at density of 1.006 kg/l to remove very-low-density lipoprotein (VLDL). Low-density lipoprotein (LDL) was precipitated with dextran sulfate-magnesium chloride from the infranatant (Penttilä et al., 1981) . High-density lipoprotein (HDL) cholesterol was analyzed from the remaining supernatant. LDL cholesterol was calculated by subtracting the amount of HDL cholesterol from the amount of cholesterol in the infranatant containing both HDL and LDL cholesterol. Cholesterol in the whole serum and in separated lipoproteins and serum triacylglycerol were analyzed using commercial kits (Boehringer GmbH Kit 237574 and 701904, Mannheim, Germany) and Kone Pro Clinical Chemistry Analyzer (Thermo Clinical Labsystems, Konelab, Finland). Serum APOA1 and B were analyzed with an immunoturbidimetric method using Kone Pro Clinical Chemistry Analyzer. Serum-free fatty acids (FFAs) were measured with enzymatic photometric method using Wako NEFA C kit (Wako Chemicals GmbH, Neuss, Germany) and Konelab Clinical Chemistry Analyzer. Plasma glucose was analyzed with enzymatic photometric method (Granutest 250; Merck, Damstadt, Germany) with the use of Kone Pro Clinical Analyzer and serum insulin with chemiluminescent immunoassay (ACS 180 Plus Automated Chemiluminescence System, Bayer Diagnostics, USA). Insulin resistance was estimated using homeostatic model where HOMA-IR ¼ (insulin (mU/l) Â glucose (mmol/l))/22.5 (Matthews et al., 1985) .
Serum cholesterol and its precursors squalene, cholestenol, desmosterol and lathosterol, and the plant sterols campesterol and sitosterol as well as cholestanol, a metabolite of cholesterol, were quantitated with gas-liquid chromatography (GLC) on a 50 m long capillary column (Ultra 1; Hewlett-Packard, Wilmington, DE, USA) using 5a-cholestane as an internal standard (Miettinen, 1988) . The squalene and non-cholesterol sterol values were expressed in terms of 10 2 Â mmol/mol cholesterol (called ratio in the text), dividing the squalene and sterol values by the cholesterol value of the same GLC run to eliminate the effects of different serum cholesterol concentrations. Samples from the fat tolerance test were analyzed as follows. The lipid classes were separated as described previously (Å gren et al., 1998) . In brief, to separate chylomicrons, 1.8 ml of plasma was overlaid with 1.6 ml of NaCl solution (d ¼ 1.006 g/ml) with Titriplex III (Merck, Darmstadt, Germany) and ultracentrifuged with a Beckman 50.2 Ti rotor (Beckman Instruments, Palo Alto, CA, USA) in a Beckman Optima L-90K ultracentrifuge (Palo Alto, CA, USA; 161C, 18 000 r.p.m., 30 min). The top 1 ml was aspirated. To separate VLDL, the chylomicron-free infranate was overlaid with 900 ml of the previously mentioned NaCl solution and ultracentrifuged with a Beckman 50.2 Ti rotor at 161C and 37 000 r.p.m. for 15 h. The top 1 ml was aspirated. LDL precipitation and analyses of cholesterol and triacylglycerol concentrations were performed as described for the fasting samples.
Statistical methods
Statistical analyses were performed with SPSS for Windows 11.5. statistics program (SPSS, Chicago, IL, USA). The results are presented as means7s.d. Normal distribution of the variables was tested with Shapiro-Wilks test and for those not complying with the assumption logarithmic transformation was used in statistical testing. The effects of dietary intervention and the interaction of intervention Â APOE group were tested with two-way general linear models for repeated measurements. Areas under the response curves (AUC) above baseline were calculated using a computer program (KaleidaGraph, Synergy Software, Reading, PA, USA). The effects of intervention, APOE genotype group and their interaction on the AUCs were tested with mixed model analyses. Spearman correlation coefficients were calculated between postprandial and fasting triacylglycerol and insulin concentrations. Two-tailed P-value o0.05 was considered as statistically significant.
The number of subjects recruited was based on the assumption of having a 1 mmol/l difference in serum fasting triacylglycerol concentration between the genotype groups after the intervention with an a level of 0.05 and statistical power of 0.80.
Results
The baseline characteristics of the study subjects are given in Table 1 . Owing to a rare occurrence of the e2 allele in the Finnish population all the available persons with the e2 allele, who fulfilled the inclusion criteria, were recruited. Therefore, the mean age of the subjects with the APOE3/2 genotype was 13 years older than of the subjects with the APOE3/3 or 3/4 genotype. At baseline, subjects with the APOE3/2 genotype had a higher plasma glucose concentration, but no significant differences in serum lipid concentrations were observed. Reported energy intake was higher during the intervention period as compared with habitual intake (Table 2) . However, there were no significant changes in body weight or BMI during the study (Table 3 ). The mean (7s.d.) actual increase on sucrose intake was 39.8718.4 g/day in the whole study group and it did not differ between the genotype groups. There were concomitant decreases in total, saturated and monounsaturated fat intakes and an increase in carbohydrate intake. The contribution of saturated, monounsaturated and polyunsaturated fat to total fat intake did not change during the intervention.
The intervention did not result in significant changes in blood pressure levels or glucose metabolism measured as plasma glucose and serum insulin concentrations and HOMA-IR index (Table 3) . Neither were any significant changes nor interactions between intervention and genotype group observed in fasting total lipid and lipoprotein lipid or APOA-1 and B concentrations at 4 or 8 weeks (Table 4) . Furthermore, ratios of serum squalene and noncholesterol sterols to cholesterol did not change (Table 5) .
Sucrose intake did not have an effect on the AUCs of total, chylomicron and VLDL triacylglycerol; chylomicron and VLDL cholesterol and insulin in the oral fat tolerance test in a subset of the participants with or without the e2 allele (Table 6, Figure 2a ). However, there was a tendency AUCs of VLDL triacylglycerols and VLDL cholesterol being higher in subjects with the APOE3/2 than in those with the APOE3/3 or 3/4 (Table 6 ). The serum FFA response to the oral fat load was not affected by the intervention or the genotype group (Figure 2b) . Fasting triacylgycerol and insulin concentrations were significantly correlated with AUC of total triacylglycerols (r ¼ 0.854 and r ¼ 0.520, respectively, both Po0.05).
Discussion
The main aim was to study the interaction of sucrose intake and polymorphism of the APOE gene in modifying fasting and postprandial serum lipid responses. A previous observational finding has suggested that subjects with the e2 allele might be more prone to hypertriglyceridemic effects of sucrose (Erkkilä et al., 2001) . Hence subjects with and without the e2 allele were identified before the commencement of the study to have a balanced number of subjects in the groups. Moderate increase in sucrose intake did not, however, induce significant changes in serum lipids in healthy subjects who were carriers or non-carriers of the e2 allele. In addition to genetic factors, many other factors like dose of sucrose, rate of introduction of sucrose, other dietary factors, BMI and sex are suggested to modify the triacylglycerol response (Hellerstein, 2002; Fried and Rao, 2003) , which can confound results in observational studies. Furthermore, the present study population consisted of healthy adults, whereas the previous finding was reported in older patients with CHD (Erkkilä et al., 2001) . Possible metabolic differences between the study populations cannot be ruled out.
A moderate increase in sucrose intake was applied, which has affected serum triacylglycerol concentrations in some studies (Liu et al., 1984; Jeppesen et al., 1997; Marckmann et al., 2000) , but not in others (Bossetti et al., 1984; Albrink and Ullrich, 1986) . However, in most of the studies higher doses of sucrose have been used and data from studies testing moderate doses of sucrose are rather limited (Fried and Rao, 2003) . Compared with average sucrose consumption in Finland (Männistö et al., 2003) , adding 40 g/day increased sucrose intake by 70-100%. The actual intake of sucrose was very close to the planned intake and dietary compliance was similar in both groups. The reduction in the intake of fat was partially achieved, thereby the reported energy intake increased. However, there were no significant changes in the body weight suggesting that during the whole study period of 8 weeks the energy intake did not exceed energy consumption. It is of note that there were more recording days during the intervention than during the habitual diet, which might have resulted in differences in accuracy of the estimations of the dietary intake.
Compared with many earlier studies of 2-4 weeks' duration (Bossetti et al., 1984; Albrink and Ullrich, 1986;  GLM model is adjusted for sex, age and weight at 0 week. f GLM model is adjusted for sex, age, weight and systolic blood pressure at 0 week. g HOMA-IR ¼ (insulin (mU/l) Â glucose (mmol/l))/22.5. Marckmann et al., 2000) , our study was relatively long. As the rise in triacylglycerol concentration is suggested to be transient (Parks and Hellerstein, 2000) , we chose to extend the duration to measure the long-term effects relevant to for example, CHD risk. However, we did not observe any significant changes in either the 4-week or the 8-week measurements. In a 6-month ad libitum feeding trial, Saris et al. (2000) did not observe significant changes in serum triacylglycerol concentration, but a small decrease in body weight, after consumption of diet containing additional 33 g/day of simple carbohydrates.
Like fasting lipid levels, there were no significant changes in postprandial lipid or insulin responses after the sucrose diet. This is in contrast to results suggesting a rise in AUC calculated from daytime profile of triacylglycerols after consumption of a high sucrose diet (90 g/day) for 24 days (Brynes et al., 2003) . Previous studies have reported that subjects with the e2 allele have higher postprandial triacylglycerol concentrations (Dallongeville et al., 1999; Reznik et al., 2002) , which was suggested also by our results. Furthermore, the APOE3/2 genotype was associated with a greater variability in the postprandial responses. Fasting triacylglycerol concentration was associated with postprandial triacylglycerol response consistent with earlier reports in a population-based sample (Sharrett et al., 2001 ) and in subjects with type II diabetes (Reznik et al., 2002) . It is suggested that dietary sucrose could increase synthesis and secretion of APOB (Abraham et al., 1994; Hellerstein, 2002) . Our results on moderate increase in sucrose intake did not suggest an effect on cholesterol metabolism either based on APO results or ratios of squalene, cholestenol, desmosterol and lathosterol to cholesterol concentration reflecting cholesterol synthesis (Miettinen et al., 1990) .
There are some limitations in this study. The results might have been affected by the older age of the subjects with the APOE3/2 genotype, which was due to availability of subjects with previous knowledge of the genotype. However, it is highly unlikely that this diminished the hypothesized difference between the genotype groups. The results can be extrapolated to healthy subjects. However, we cannot exclude the possibility that subjects with impaired lipid or glucose metabolism might have different responses. Furthermore, the number of study subjects (n ¼ 34) might have limited the power to detect an effect.
The results showed that in healthy subjects, moderate increase in sucrose intake does not significantly affect serum fasting or postprandial lipid responses. The e2 allele did not modify serum lipid response to dietary sucrose. The mean (7s.e.m.) postprandial plasma triacylglycerol (a) and serum FFA (b) concentrations before and after the sucrose diet in subjects with or without e2 allele (& subjects with APOE 3/2 at 0 week, ' subjects with APOE 3/2 at 8 week, J subjects with APOE 3/3 or 3/4 at 0 week and K subjects with APOE 3/3 or 3/4 at 8 week).
